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Abstract
 
The 
 
ob
 
 gene product, leptin, is a signaling factor regulating
body weight and energy balance. 
 
ob
 
 gene expression in ro-
dents is increased in obesity and is regulated by feeding pat-
terns and hormones, such as insulin and glucocorticoids. In
humans with gross obesity, 
 
ob
 
 mRNA levels are higher, but
other modulators of human 
 
ob
 
 expression are unknown. In
view of the importance of peroxisome proliferator–activated
receptor 
 
g
 
 (PPAR
 
g
 
) in adipocyte differentiation, we ana-
lyzed whether 
 
ob
 
 gene expression is subject to regulation by
factors activating PPARs. Treatment of rats with the
PPAR
 
a
 
 activator fenofibrate did not change adipose tissue
and body weight and had no significant effect on 
 
ob
 
 mRNA
levels. However, administration of the thiazolidinedione
BRL49653, a PPAR
 
g
 
 ligand, increased food intake and adi-
pose tissue weight while reducing 
 
ob
 
 mRNA levels in rats in
a dose-dependent manner. The inhibitory action of the thia-
zolidinedione BRL49653 on 
 
ob
 
 mRNA levels was also ob-
served in vitro. Thiazolidinediones reduced the expression
of the human 
 
ob
 
 promoter in primary adipocytes, however,
in undifferentiated 3T3-L1 preadipocytes lacking endoge-
nous PPAR
 
g
 
, cotransfection of PPAR
 
g
 
 was required to ob-
serve the decrease. In conclusion, these data suggest that
PPAR
 
g
 
 activators reduce 
 
ob
 
 mRNA levels through an effect
of PPAR
 
g
 
 on the 
 
ob
 
 promoter. (
 
J. Clin. Invest.
 
 1996. 98:
1004–1009.) Key words: obesity 
 
•
 
 antidiabetic 
 
•
 
 adipocyte 
 
•
 
adipose
 
Introduction
 
Obesity, a disorder of energy balance, represents a major
health problem and is usually associated with complications in-
cluding cardiovascular disease, diabetes, and an increased
mortality rate (1). Obesity or predisposition to obesity has a
strong genetic component (2). In the 
 
ob
 
/
 
ob
 
 mouse, a single
gene mutation results in profound obesity that is often accom-
panied by diabetes (3). Using positional cloning techniques,
Friedman and colleagues identified the mouse 
 
ob
 
 gene and its
human homologue (4) and demonstrated that expression of
the 
 
ob
 
 gene is limited to adipose tissue. In mutant SM/Ckc-
 
1
 
Dac
 
ob
 
2J
 
/
 
ob
 
2J
 
 mice, a genomic alteration results in the com-
plete absence of 
 
ob
 
 mRNA, whereas in C57BL/6J-
 
ob
 
/
 
ob
 
 mice,
a nonsense mutation results in a truncated, nonfunctional pro-
tein. Studies with specific antibodies confirmed the presence of
the 
 
ob
 
 gene product, leptin, in plasma of normal mice and its
absence in plasma of 
 
ob
 
/
 
ob
 
 mutants (5). Before the identifica-
tion of the 
 
ob
 
 gene, a role for leptin as a satiety factor was pro-
posed based on data derived from parabiosis experiments (6).
When 
 
ob
 
/
 
ob
 
 mice were made parabiotic with normal mice,
they curbed their eating and lost weight, suggesting that they
were responsive to a blood-borne satiety factor produced by
the normal partner (6). Furthermore, leptin injection reduces
food intake, increases energy expenditure, induces weight loss,
and normalizes metabolic parameters such as insulin and glu-
cose in wild-type, diet-induced obese and C57BL/6J 
 
ob
 
/
 
ob
 
mice (5, 7–10).
A potential mechanism of leptin’s signaling action was elu-
cidated recently when a leptin receptor was cloned (11, 12).
This receptor is related to the gp130 signal transducing compo-
nent of the IL-6, G-CSF, and LIF cytokine receptors (11). The
receptor is highly expressed in the choroid plexus and maps to
a position on mouse chromosome 4 encompassing the 
 
db
 
 lo-
cus. It is therefore tempting to speculate that leptin provides
the central nervous system with a signal triggering multiple ef-
fector pathways leading to leptin’s pleiotropic effects.
To completely understand leptin’s role in energy metabo-
lism, it is necessary to delineate the factors involved in 
 
ob
 
 gene
regulation. Recent studies have demonstrated that the expres-
sion of the 
 
ob
 
 gene is itself controlled by the nutritional status
of the animal. Fasting reduces, whereas food intake increases,
 
ob
 
 gene expression (13–16), an effect accounted for by changes
in plasma insulin levels (14, 16). Glucocorticoids have also
been shown to regulate 
 
ob
 
 gene expression (17, 18). Further-
more, in overtly obese humans (19–23) and in several animal
models of obesity, such as the 
 
db
 
/
 
db
 
 mouse, Zucker 
 
fa
 
/
 
fa
 
 rats,
and VMH-lesioned rats (5, 13, 24–28), which do not appear to
respond to leptin, 
 
ob
 
 mRNA and circulating leptin levels are
increased. These findings suggest that upregulation of 
 
ob
 
mRNA levels occurs as a homeostatic mechanism.
Since the 
 
ob
 
 gene is exclusively expressed in adipocytes, we
have initiated studies to examine the role of adipogenic factors
in the expression and regulation of the 
 
ob
 
 gene. The expres-
sion of two important adipocyte transcription factors, peroxi-
some proliferator–activated receptor 
 
g
 
 (PPAR
 
g
 
)
 
1
 
 and C/EBP
 
a
 
,
is induced during adipocyte differentiation and these factors
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are maintained in the mature adipocyte. Several adipocyte-
specific genes have binding sites for these factors in their pro-
moters and have been shown to be transcriptionally responsive
to chemical modulators of these factors (reviewed in reference
29). Recent studies by our group and others have character-
ized the role of C/EBP
 
a
 
 in 
 
ob
 
 gene expression, an effect medi-
ated by a C/EBP site in the proximal 
 
ob
 
 gene promoter (30,
31). The present study was undertaken to better understand
the role of PPAR
 
g
 
, the other key transcription factor impli-
cated in the determination of the adipocyte phenotype, in 
 
ob
 
gene expression. In these studies, we demonstrate that expres-
sion of the 
 
ob
 
 gene is reduced by PPAR
 
g
 
 and its activators
both in vivo and in vitro.
 
Methods
 
Reagents. 
 
BRL 49653 was synthesized at Ligand Pharmaceuticals
(San Diego, CA), whereas fenofibrate was a generous gift of Dr.
Alan Edgar of Fournier (Dijon, France). All other reagents were ob-
tained from the usual sources.
 
Animal studies. 
 
Adult Sprague-Dawley rats were divided in
groups of four animals each. They were group housed and accus-
tomed to a 12:12 h day–night illumination cycle (light from 8 a.m. to 8
p.m.). In one series of experiments, the effects of BRL 49653 were an-
alyzed. In the first study, rats received BRL 49653 (1, 2, or 5 mg/kg
per d) or vehicle alone (1% carboxymethylcellulose) for 7 d by gav-
age. In a subsequent experiment, rats were dosed with either 5 or 10
mg/kg per d. In a third study, controls were compared with animals
that received 0.5% wt/wt of fenofibrate mixed with their food over 14
d. In a final study, we analyzed adipose tissue 
 
ob
 
 mRNA levels in rats
fed a high-fat diet containing 20% hydrogenated coconut oil (con-
trols) or 20% menhaden (fish) oil for 3 mo. All animals were killed by
exsanguination under ether anesthesia between 8 and 10 a.m. Epi-
didymal adipose tissue was removed, rinsed with 0.9% NaCl, and fro-
zen in liquid nitrogen until RNA preparation.
 
Cell culture. 
 
Primary rat adipocytes were obtained exactly as de-
scribed by Hajduch et al. (32). Standard cell culture conditions were
used to maintain 3T3-L1 cells obtained from American Type Culture
Collection (Rockville, MD). BRL 49653 and fenofibric acid (in
DMSO) were added to the medium at the appropriate concentrations
for the times indicated while control cells received vehicle only.
 
mRNA analysis. 
 
RNA preparation, Northern and dot blot hy-
bridizations, and quantification of total cellular RNA were per-
formed as described previously (16). 
 
ob
 
 mRNA was detected using a
labeled mouse 
 
ob
 
 cDNA fragment spanning nucleotides 
 
1
 
50 to 
 
1
 
659
(17), and a human 
 
g
 
-actin cDNA clone (33) was used as a control for
normalization.
 
Analysis of promoter activity. 
 
To test the activity of the human
 
ob
 
 promoter in vitro, reporter constructs were made. A 7-kb HindIII
fragment of the human genomic Pl clone 5135 hybridizing to an oligo
containing the 20 bp located at the 5
 
9
 
 end of the 
 
ob
 
 cDNA was sub-
cloned into the HindIII site of pBluescript (Stratagene Inc., San Di-
ego, CA). From this construct, a 3-kb fragment, containing sequences
from 
 
2
 
2924 (5
 
9
 
 HindIII site) to 
 
1
 
31 relative to the transcription start
site, was amplified by PCR with a T7 primer and SMREV2 (5
 
9
 
-
CGCGGGAAGCTTGCCTTGCAACCGTTGGCGCTGCG-3
 
9
 
). The
PCR product was digested with HindIII and ligated into the HindIII
site of the promoterless luciferase reporter vector pGL3-Basic (Promega
Corp., Madison, WI) to generate pGL3-OB1 and sequenced to confirm
orientation (30, 34). The hamster pSG5-cgP-PAR
 
g
 
 expression vector
has been described elsewhere (35). Transfections were performed us-
ing either standard calcium phosphate precipitation techniques for
3T3-L1 preadipocytes (36) or electroporation for primary adipocytes
(37). A cytomegalovirus-driven 
 
b
 
-galactosidase expression vector
was used to normalize for transfection efficiency. Luciferase assays
were carried out exactly as described previously (37).
 
Results
 
Food intake and adipose tissue weights increase and ob mRNA
levels decrease after administration of PPAR
 
g
 
 but not PPAR
 
a
 
activators to rats.
 
Adipocyte differentiation has been shown to
be determined by the coordinately acting transcription factors
PPAR
 
g
 
 (30, 38, 39) and various members of the C/EBP family
(reviewed in reference 40). Previous studies by our group (30)
and others (31) demonstrated the critical role of C/EBP
 
a
 
 in
the expression of the 
 
ob
 
 gene. In these studies, we addressed
the role of PPAR
 
g
 
 in 
 
ob
 
 gene regulation. We first tested the
effects of the antidiabetic thiazolidinedione BRL 49653, previ-
ously shown to be a high affinity ligand for PPAR
 
g
 
 (41, 42), on
the expression of the 
 
ob
 
 gene in vivo in rats. In animals receiv-
ing BRL 49653 at increasing doses (0, 1, 2, and 5 mg/kg per d)
over 7 d, no change in either body or liver weight was observed
(Table I). However, a dose-dependent increase in epidydimal
fat pad weight was observed after BRL 49653 treatment (Ta-
ble I). These observations are consistent with previously re-
ported activities of the thiazolidinedione antidiabetic agents to
induce adipocyte differentiation and increase adipose tissue
mass (43–47). In this experiment, which used relatively low
doses of BRL, food intake showed a tendency to decrease, al-
though no statistical significance was obtained. To unequivo-
cally establish that BRL 49653 had an effect on food intake we
administered higher doses of BRL 49653 (5, 10, 20 mg/kg per
d) to rats over 7 d and recorded food intake on a daily basis. In
this experiment, administration of BRL at doses of 5, 10, or 20
mg/kg per d was associated with a significant increase in food
intake (Fig. 1).
To analyze whether the effect of thiazolidinediones on adi-
pose tissue involves changes in 
 
ob
 
 expression, we analyzed 
 
ob
 
mRNA in epidydimal fat pads of these rats. 
 
ob
 
 mRNA levels
decreased by 40% in rats treated with BRL 49653 at 5 mg/kg
per d (Fig. 2). Other potential conditions resulting in activation
of PPAR
 
g
 
, such as administration of a diet enriched in fish oils
(20% wt/wt in food, 3 mo), also decreased 
 
ob
 
 mRNA expres-
sion significantly by 33% (Fig. 2). This indicates a possible role
for fatty acid–derived PPAR activators in the regulation of 
 
ob
 
gene expression. In contrast to the results obtained with thia-
zolidinediones and fish oils, administration of the PPAR
 
a
 
 acti-
vator, fenofibrate (0.5% wt/wt in food for 14 d), did not result
in a reduction of 
 
ob
 
 mRNA levels (Fig. 2). Treatment of ani-
 
Table I. Effects of Administration of Different Doses of BRL 
49653 on Body Mass, Liver Weight, and Weight of the 
Epidydimal Fat Pad
 
Body mass Epidydimal fat Liver
 
grams grams grams
 
Control 344622 2.560.3 16.861.3
BRL 49653
(1 mg/kg per d) 355621 3.360.2* 17.961.3
BRL 49653
(2 mg/kg per d) 361618 3.860.5* 18.960.6
BRL 49653
(5 mg/kg per d) 33869 4.060.6* 17.461.8
*Statistically different from control, P , 0.05.
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mals with fenofibrate did not result in a change in body or adi-
pose tissue weight, whereas the typical increase in liver weight
(from 13.860.5 to 19.762.5 grams) known to occur after treat-
ment with peroxisome proliferators such as fenofibrate was
observed (48). Furthermore, this increase in liver weight was
associated with a sevenfold induction in liver acylCoA oxidase
mRNA levels indicating that fenofibrate was active (49) (data
not shown). The effect of BRL 49653 on ob mRNA expression
was furthermore dose dependent, being most pronounced at a
dose of 5 mg/kg per d (Fig. 3).
PPARg activators control ob mRNA expression in cultured
primary adipocytes. To determine whether the in vivo changes
in ob gene expression are the result of a direct PPARg effect
on adipocyte ob gene expression, we evaluated the effects of
BRL 49653 (100 mM; 24 h) and the PPARa selective peroxi-
some proliferator, fenofibric acid (250 mM; 24 h), on ob
mRNA expression in primary rat adipocytes. Whereas BRL
49653 reduced ob mRNA expression significantly in three in-
dependent experiments, no effect of fenofibrate on ob mRNA
levels was detected (Fig. 4). These results thus suggest that the
in vivo effects of the PPARg ligand BRL 49653 are due to a di-
rect cellular effect on adipocyte ob gene expression.
PPARg modulates the ob promoter at the transcriptional
level. We next studied the effects of coexpression of PPARg
in the presence or absence of PPAR activators on the z 3 kb
human ob promoter construct pGL3-OB1 (30). In primary rat
adipocytes, cotransfection of the PPARg expression vector
(pSGS-cgPPARg) in the absence of activators had no effect
(Fig. 5 A). When the thiazolidinedione, pioglitazone, was
added (10 mM), a 30% decrease in ob promoter activity was
observed. Combination of PPARg plus pioglitazone led to an
additional decrease to z 50% (Fig. 5 A). When a more potent
thiazolidinedione, such as BRL 49653 (10 mM), was used in rat
primary adipocytes, promoter activity was reduced 60% and
cotransfection of PPARg had no further effect, suggesting the
Figure 1. BRL 49653 increases food intake in rats. Rats (groups of 
5) were administered either 0, 5, 10, or 20 mg/kg per d of BRL 49653 
and the effect on food intake was recorded daily.
Figure 2. PPAR activators reduce ob gene expression in rats. Effect 
of administration of BRL 49653 (BRL; 10 mg/kg per d during 7 d), 
fenofibrate (FF; 0.5% wt/wt during 14 d), or a diet enriched in fish 
oils (FO; 20% wt/wt for 3 mo) on ob mRNA levels in rat adipose tis-
sue. Adipose tissue RNA was isolated and mRNA levels, normalized 
to a control mRNA, and quantified as indicated in the Methods sec-
tion. Results shown are the mean6SD of groups of four animals. In-
sets show representative autoradiograms of Northern blots used for 
quantitation. *P , 0.05.
Figure 3. Dose-dependent effect of BRL 49653 on ob mRNA levels. 
(A) Dose-dependent effect of BRL 49653 (BRL; 0, 1, 2, 5 mg/kg per 
d) administered during 7 d to male rats on ob gene expression. Adi-
pose tissue RNA was isolated and mRNA levels, normalized to a 
control mRNA, quantified as indicated in the Methods section. The 
mean6SD for four animals is shown. *P , 0.05. (B) Representative 
Northern blots, from an independent experiment, probed with an ob-
specific probe (top) or a probe for 36B4 (bottom), a gene whose ex-
pression is not affected by the differentiation state (38).
Figure 4. PPAR activators decrease ob gene expression in primary 
adipocytes. (A) Effect of treatment with BRL 49653 (100 mM, 24 h) 
and fenofibric acid (250 mM, 24 h) on ob mRNA levels in rat primary 
adipocytes. RNA was isolated and quantified as indicated in the 
Methods section. The mean of three independent experiments is 
shown taking the controls as 100%. The BRL 49653 effect was signif-
icant at P , 0.05. (B) Representative Northern blot showing the ef-
fects of BRL 49653 and fenofibric acid on ob mRNA levels in pri-
mary rat adipocytes. Blots were reprobed with g-actin as a control.
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presence of saturating amounts of endogenous PPARg in the
mature adipocyte (Fig. 5 A).
Treatment of undifferentiated 3T3-L1 preadipocytes with
thiazolidinediones by themselves had no effect on ob pro-
moter activity thereby indicating and confirming observations
that these cells, unlike primary adipocytes, do not contain
PPARg (38). Cotransfection of PPARg in undifferentiated
3T3-L1 cells, however, consistently reduced the activity of the
pGL3-OB1 promoter construct (Fig. 5 B). The degree of inhi-
bition was dependent on the amount of PPARg cotransfected.
Only a slight additional effect of addition of the PPARg ligand
BRL 49653 was observed (Fig. 5 B).
Discussion
The association of murine obesity with mutations in the ob
gene has generated intense interest in molecular studies aimed
at delineating factors potentially involved in human obesity. In
this study, we determined whether the expression of the ob
gene is under the control of PPARg, a key transcription factor
involved in adipocyte-specific gene expression. PPREs have
been characterized in several genes involved in the control of
lipid and fatty acid metabolism (reviewed in reference 29). In
addition, several key adipocyte genes have been shown to be
induced by PPAR activators and to contain functional PPREs
in their regulatory sequences (e.g., lipoprotein lipase, Schoon-
jans, K., and J. Auwerx, unpublished observations; 36, 38, 50,
51). Furthermore, it was recently reported that antidiabetic
thiazolidinediones (41, 42) and prostaglandin derivatives (42,
52) are direct and specific ligands for PPARg2. The identifica-
tion of prostaglandins as the endogenous PPARg2 ligand and
the capacity of other fatty acids to activate this transcription
factor provides a mechanistic explanation of the ability of fatty
acids (38, 53, 54) and arachidonic acid (55) to induce adipocyte
differentiation.
Despite the fact that ob expression is associated with the
differentiated adipocyte phenotype and PPARg is a key tran-
scription factor triggering and maintaining this phenotype,
PPARg activation does not induce ob expression. To the con-
trary, PPARg ligands decrease ob expression both when ad-
ministered in vivo and when added to cultured adipocytes in
vitro. Furthermore, PPARg decreases transcription of a re-
porter gene driven by z 3,000 bp of the human ob promoter.
This negative effect on ob gene expression appears to be spe-
cific for compounds capable of activating PPARg, since fenofi-
brate, a potent PPARa activator, has no effect on ob gene ex-
pression. PPARs heterodimerize with RXRs and these
heterodimers exert their effects on transcription via interac-
tion with a PPRE, composed of a direct repeat of the nuclear
receptor hexanucleotide core recognition motif spaced by 1
nucleotide (reviewed in reference 29). We were unable to
identify by homology search a consensus PPRE in the ob gene
promoter. In view of the rather unusual negative effects of
PPARg by thiazolidinediones on ob gene transcription and the
absence of a consensus PPRE, it will be important to identify
the molecular mechanism underlying this negative regulation.
This phenomenon is reminiscent of the negative effects of
PPARa modulators on apo C-III expression in the liver (49,
56). It is therefore tempting to speculate that the repressive ef-
fects of PPARg on the human ob gene promoter might be me-
diated through interactions with positive modulators of ob
transcription, such as C/EBPa or Sp1 (30).
The observed decrease in ob gene expression after treat-
ment with BRL 49653 in the presence of an increase in adipose
tissue mass is very interesting and suggests that body mass and
ob gene expression can be regulated in opposite fashion (e.g.,
by pharmacological treatment with PPARg activators). This
situation is in contrast with both the overexpression of ob
mRNA observed in several obese animals, such as the db/db
mice, Zucker fa/fa rats, and VMH-lesioned rats (5, 13, 24–28),
and with the positive correlation between body mass index and
ob mRNA or plasma leptin observed in humans (19–23). The
physiological importance of this discordance between ob
mRNA levels and adipose tissue mass after thiazolidinedione
treatment is unclear at present. It is, however, tempting to
speculate that the uncoupling of adipose tissue mass and ob
gene expression might be implicated in mediating the effects of
thiazolidinediones on insulin resistance.
In vivo, PPAR’s activities to reduce leptin levels may lead
to increased caloric uptake, thus favoring energy storage into
adipocytes. In that context, the effects of PPARg modulators
on ob gene expression and other adipocyte-specific target
genes, such as lipoprotein lipase (Schoonjans, K., and J. Au-
werx, unpublished observations), fatty acid transporter protein
(Martin, G., B. Staels, and J. Auwerx, unpublished observa-
tions), aP2 (39), and acyl-CoA synthetase (36, 51) will lead to
increased energy uptake and storage in the adipocyte. The re-
duction in ob gene expression after PPARg activation might
therefore explain two well-known but ill-understood phenom-
ena. First, the PPAR-mediated reduction in ob gene expres-
sion might underly the increase in adipocyte differentiation
and adiposity associated with treatment with thiazolidinedione
antidiabetic agents (43–47). Results from our experiments con-
firm the adipose tissue weight gain in animals receiving BRL
49653, showing a significant dose-dependent increase in these
animals. The absence of an effect on total body weight in this
study, in contrast to other studies reported in the literature
Figure 5. ob promoter activity is regulated by PPARg. (A) Promoter 
activity of the pGL3-OB1 construct was analyzed in primary rat adi-
pocytes. Luciferase activity was determined in cells transfected with 
either 5 mg of pSG5-cgPPARg or the empty pSG5 expression vector 
in the presence or absence of 10 mM pioglitazone or 10 mM BRL 
49653. Cells were exposed to the compounds for 24 h. *P , 0.05;
**P , 0.01. (B) Promoter activity of the pGL3-OB1 (2 mg) construct 
was analyzed in 3T3-L1 preadipocytes. Luciferase activity was deter-
mined in cells cotransfected with either 2 mg of pSGS-cgPPARg or 
the empty pSG5 expression vector in the presence or absence of 10 
mM BRL 49653. Cells were exposed to BRL 49653 for 24 h. The 
mean of four points is shown. Experiments were performed at least 
three times. *P , 0.05.
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(57–59), is most likely due to the short time BRL 49653 was
administered in our experiments. Second, it is tempting to
speculate that the increase in fatty acids delivered to the adipo-
cyte after a high-fat meal could be involved in stimulating adi-
pose PPARg activity. The ensuing decrease in ob gene expres-
sion and leptin levels would be associated with a smaller
suppression of appetite. In fact, clinical data have shown that
high fat meals are known to be less satiating than equicaloric
carbohydrate-rich meals (60, 61).
In conclusion, we have demonstrated that ob gene expres-
sion is reduced both in vivo and in vitro by PPARg activators.
These compounds have a direct effect on the ob promoter.
Knowledge of sequence elements involved in this regulation
and identification of factors such as PPARg regulating ob gene
expression should be of major importance in our understand-
ing of adipocyte physiology and obesity.
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